

Kojiro Ohba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8541388/publications.pdf>

Version: 2024-02-01

44
papers

520
citations

623574

14
h-index

713332

21
g-index

49
all docs

49
docs citations

49
times ranked

846
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of major venous bleeding during minimally invasive pelvic surgery: A proposed protocol for "What should we do next?" International Journal of Urology, 2022, 29, 177-179.	0.5	2
2	Alternative Treatment with Every-Other-Day Dosing of Sunitinib for Metastatic Renal Cell Carcinoma: Extended Follow-Up. Urologia Internationalis, 2022, , 1-7.	0.6	0
3	Relationship between Urinary Calcium Excretion and Lower Urinary Tract Symptoms. Metabolites, 2022, 12, 229.	1.3	2
4	Intra- and post-operative management of pancreatic injury during laparoscopic nephrectomy. International Journal of Urology, 2022, 29, 905-907.	0.5	1
5	Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder. Medicina (Lithuania), 2022, 58, 825.	0.8	1
6	Pharmacological Effects and Potential Clinical Usefulness of Polyphenols in Benign Prostatic Hyperplasia. Molecules, 2021, 26, 450.	1.7	18
7	External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort. Japanese Journal of Clinical Oncology, 2021, 51, 810-818.	0.6	0
8	Presurgical bladder wall thickness is a useful marker to predict the postsurgical improvement of symptoms in patients with pelvic organ prolapse-related overactive bladder. LUTS: Lower Urinary Tract Symptoms, 2021, 13, 347-355.	0.6	4
9	Management of venous bleeding during laparoscopic renal surgery: Experiences in the usefulness of soft coagulation and TachoSil. International Journal of Urology, 2021, 28, 976-977.	0.5	3
10	Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma. Journal of Geriatric Oncology, 2021, 12, 834-837.	0.5	1
11	Dialysis Access and Preemptive Kidney Transplantation. Kidney and Dialysis, 2021, 1, 79-87.	0.5	0
12	Editorial Comment to Spontaneous regression of multiple pulmonary metastases accompanied by normalization of serum immune markers following cytoreductive nephrectomy in a patient with clear-cell renal cell carcinoma. IJU Case Reports, 2021, 4, 100-100.	0.1	0
13	Pathological Significance of Macrophages in Erectile Dysfunction Including Peyronie's Disease. Biomedicines, 2021, 9, 1658.	1.4	6
14	Efficacy of propiverine hydrochloride for urinary incontinence after robot-assisted or laparoscopic radical prostatectomy. Canadian Journal of Urology, 2021, 28, 10706-10712.	0.0	0
15	Effect of oral intake of royal jelly on endothelium function in hemodialysis patients: study protocol for multicenter, double-blind, randomized control trial. Trials, 2021, 22, 950.	0.7	3
16	Mechanisms Underlying the Inhibition of Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and the Correlation between Macrophage Colony Stimulating Factor and Inflammatory Mediators. Medical Sciences (Basel, Switzerland), 2020, 8, 43.	1.3	0
17	Pathological and Pharmacological Roles of Mitochondrial Reactive Oxygen Species in Malignant Neoplasms: Therapies Involving Chemical Compounds, Natural Products, and Photosensitizers. Molecules, 2020, 25, 5252.	1.7	7
18	Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer. Cancers, 2020, 12, 3776.	1.7	8

#	ARTICLE	IF	CITATIONS
19	Molecular Mechanisms of the Anti-Cancer Effects of Isothiocyanates from Cruciferous Vegetables in Bladder Cancer. <i>Molecules</i> , 2020, 25, 575.	1.7	34
20	Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma. <i>Cancer Science</i> , 2020, 111, 2460-2471.	1.7	7
21	Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF α and TGF β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial. <i>Molecular and Clinical Oncology</i> , 2020, 13, 29.	0.4	9
22	Pathological roles of β -Met in bladder cancer: Association with cyclooxygenase 2 , heme oxygenase 1 , vascular endothelial growth factor A and programmed death ligand 1 . <i>Oncology Letters</i> , 2020, 20, 135-144.	0.8	3
23	Periodontal Disease in Patients Receiving Dialysis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3805.	1.8	28
24	Ultrasound-Proven Severe Synovitis Induced by PD-1 Inhibitor Therapy in a Patient Predisposed to Seronegative Inflammatory Arthritis. <i>Case Reports in Rheumatology</i> , 2019, 2019, 1-3.	0.2	1
25	Pathological Characteristics of Periodontal Disease in Patients with Chronic Kidney Disease and Kidney Transplantation. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3413.	1.8	39
26	Four-weekly Low-dose Gemcitabine and Paclitaxel in Patients With Platinum-resistant Urothelial Cancer and Performance Status 2/3. <i>In Vivo</i> , 2019, 33, 2217-2224.	0.6	2
27	A Review of Oxidative Stress and Urinary Dysfunction Caused by Bladder Outlet Obstruction and Treatments Using Antioxidants. <i>Antioxidants</i> , 2019, 8, 132.	2.2	34
28	The Pathological Significance and Prognostic Roles of Thrombospondin-1, and -2, and 4N1K-peptide in Bladder Cancer. <i>Anticancer Research</i> , 2019, 39, 2317-2324.	0.5	12
29	Oral Intake of Royal Jelly Has Protective Effects Against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 2.	0.7	22
30	Efficacy and safety of sunitinib alternate day regimen in patients with metastatic renal cell carcinoma in Japan: Comparison with standard 4/2 schedule. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 153-158.	0.7	19
31	Pathological significance and prognostic roles of densities of CD57+ cells, CD68+ cells, and mast cells, and their ratios in clear cell renal cell carcinoma. <i>Human Pathology</i> , 2018, 79, 102-108.	1.1	19
32	High Consumption of Green Tea Suppresses Urinary Tract Recurrence of Urothelial Cancer via Down-regulation of Human Antigen-R Expression in Never Smokers. <i>In Vivo</i> , 2018, 32, 721-729.	0.6	7
33	Anticancer Effects of Green Tea and the Underlying Molecular Mechanisms in Bladder Cancer. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 87.	0.7	47
34	Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy. <i>Anticancer Research</i> , 2018, 38, 1629-1635.	0.5	9
35	A Mini-Review of Reactive Oxygen Species in Urological Cancer: Correlation with NADPH Oxidases, Angiogenesis, and Apoptosis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2214.	1.8	44
36	The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with β -1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men. <i>BMC Urology</i> , 2016, 16, 45.	0.6	24

#	ARTICLE	IF	CITATIONS
37	Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer. <i>Medical Oncology</i> , 2015, 32, 235.	1.2	9
38	Met in Urological Cancers. <i>Cancers</i> , 2014, 6, 2387-2403.	1.7	18
39	Recovery from life-threatening pelvic organ prolapse in an 80-year-old Japanese woman: a case report. <i>Clinical Case Reports (discontinued)</i> , 2014, 2, 118-121.	0.2	2
40	Left atrial metastasis of renal cell carcinoma: a case report and review of the literature. <i>BMC Research Notes</i> , 2014, 7, 520.	0.6	15
41	High expression of Twist is associated with tumor aggressiveness and poor prognosis in patients with renal cell carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 3158-65.	0.5	20
42	Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 451-459.	1.1	8
43	Clinical significance and predictive value of prostaglandin E2 receptors (EPR) 1 - 4 in patients with renal cell carcinoma. <i>Anticancer Research</i> , 2011, 31, 597-605.	0.5	7
44	Pathological function of prostaglandin E2 receptors in transitional cell carcinoma of the upper urinary tract. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 822-829.	1.4	13